AstraZeneca PLC (AZN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

AstraZeneca ( AZN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, AstraZeneca rose 67 cents (1.4%) to $48.11 on average volume. Throughout the day, two million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $47.56-$48.23 after having opened the day at $47.60 as compared to the previous trading day's close of $47.44. Other companies within the Health Care sector that increased today were: Graymark Healthcare ( GRMH), up 33.9%, Cyclacel Pharmaceuticals ( CYCC), up 27.2%, MEI Pharma ( MEIP), up 23.7%, and Galectin Therapeutics ( GALT), up 18.5%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases worldwide. AstraZeneca has a market cap of $59.08 billion and is part of the drugs industry. The company has a P/E ratio of 6.4, below the average drugs industry P/E ratio of 7.5 and below the S&P 500 P/E ratio of 17.7. Shares are up 2.5% year to date as of the close of trading on Tuesday. Currently there is one analyst that rates AstraZeneca a buy, two analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Questcor Pharmaceuticals ( QCOR), down 47.8%, USMD Holdings ( USMD), down 26.4%, Somaxon Pharmaceuticals ( SOMX), down 11.2%, and Idenix Pharmaceuticals ( IDIX), down 9.4%, were all laggards within the health care sector with WellCare Health Plans ( WCG) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec